Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 89 Show results per page	View Search Criteria \| Help With Results


1.		Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				1 to 18				Other				EUDRACT 2004-001647-30 PHRC/04-04, CIC0203/043, NCT00287105


2.		Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CSTI571BDE28 NCT00372476


3.		Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CSTI571BDE57 NCT00427583


4.		Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CRAD001C2454 NCT00510354

Last Modified: 11/27/2006 First Published: 2/21/2003


5.		Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				III-MK-CML-IV EU-20248, NCT00055874

Last Modified: 10/23/2007 First Published: 1/24/2005


6.		Phase III Randomized Study of Adjuvant Imatinib Mesylate Versus Observation Only in Patients With Completely Resected Localized Gastrointestinal Stromal Tumor at Intermediate- or High-Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EORTC-62024 ISG-62024, FRE-FNCLCC-EORTC-62024, GEIS-EORTC-62024, EUDRACT-2004-001810-16, NCT00103168


7.		Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				SSGXVIII/AIO NCT00116935


8.		STI571 ProspectIve RandomIzed Trial: SPIRIT

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				030482 NCT00219739

Last Modified: 10/11/2008 First Published: 5/5/2006


9.		Phase III Randomized Study of Imatinib Mesylate With Versus Without Bevacizumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				SWOG-S0502 S0502, CALGB-S0502, CAN-NCIC-S0502, NCT00324987


10.		Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CSTI571AAT06 NCT00327262

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute